717 related articles for article (PubMed ID: 31623662)
21. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
22. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
23. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
24. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
25. POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Li Y; Yang Q; Liu Y; Yi H; Ju Y; Qi G
Invest New Drugs; 2023 Aug; 41(4):556-563. PubMed ID: 37318657
[TBL] [Abstract][Full Text] [Related]
26. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
27. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
Lavoie JM; Black PC; Eigl BJ
J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407
[TBL] [Abstract][Full Text] [Related]
28. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
29.
Brown LC; Tucker MD; Sedhom R; Schwartz EB; Zhu J; Kao C; Labriola MK; Gupta RT; Marin D; Wu Y; Gupta S; Zhang T; Harrison MR; George DJ; Alva A; Antonarakis ES; Armstrong AJ
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653800
[TBL] [Abstract][Full Text] [Related]
30. GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers.
Li GX; Chang RZ; Liu TT; Jin GN; Lu K; Yong TY; Li Z; Liu JH; Zhang B; Zhang WG; Ding ZY
Cancer Gene Ther; 2024 Apr; 31(4):586-598. PubMed ID: 38267623
[TBL] [Abstract][Full Text] [Related]
31. Loss of ten-eleven translocation 1 (TET1) expression as a diagnostic and prognostic biomarker of endometrial carcinoma.
Liu NT; Perng CL; Chou YC; Ko PS; Lin YJ; Lin YC; Chang CC; Wang YC; Shang HS; Chao TK
PLoS One; 2021; 16(11):e0259330. PubMed ID: 34731191
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohorts.
Long JY; Li RZ; Wang DX; Liu H; Tian J; Ding ZN; Yan LJ; Dong ZR; Hong JG; Tian BW; Han CL; Zhao HT; Li T
Int Immunopharmacol; 2024 Jan; 126():111281. PubMed ID: 38061115
[TBL] [Abstract][Full Text] [Related]
33. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
[TBL] [Abstract][Full Text] [Related]
35. PTCH1 mutation as a potential predictive biomarker for immune checkpoint inhibitors in gastrointestinal cancer.
Deng S; Gu H; Chen Z; Liu Y; Zhang Q; Chen D; Yi S
Carcinogenesis; 2024 May; 45(5):351-357. PubMed ID: 38310539
[TBL] [Abstract][Full Text] [Related]
36. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
37. The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer.
Fan Y; Ying H; Wu X; Chen H; Hu Y; Zhang H; Wu L; Yang Y; Mao B; Zheng L
Cancer Biol Med; 2020 Nov; 17(4):1002-1013. PubMed ID: 33299649
[TBL] [Abstract][Full Text] [Related]
38. Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.
Long J; Wang D; Yang X; Wang A; Lin Y; Zheng M; Zhang H; Sang X; Wang H; Hu K; Zhao H
BMC Med; 2021 Jul; 19(1):154. PubMed ID: 34284787
[TBL] [Abstract][Full Text] [Related]
39. MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer.
Sun L; Li M; Deng L; Niu Y; Tang Y; Wang Y; Guo L
Front Pharmacol; 2021; 12():625593. PubMed ID: 33927616
[No Abstract] [Full Text] [Related]
40. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]